Stocksigma LogoStocksigma Logo

Zydus Therapeutics Reports Positive Phase 2b Trial Data for Saroglitazar in MASH

On 6th Nov'26, Zydus Therapeutics reported Phase 2b EVIDENCES X trial results for saroglitazar in adults with MASH and F2鈥揊3 fibrosis

Zydus Therapeutics Reports Positive Phase 2b Trial Data for Saroglitazar in MASH

Zydus Lifesciences Ltd 路 Press Release 路 07 Nov 2026, 12:27 am

Zydus Therapeutics Reports Positive Phase 2b Trial Data for Saroglitazar in MASH On 6th Nov'26, Zydus Therapeutics reported Phase 2b EVIDENCES X trial results for saroglitazar in adults with MASH and F2鈥揊3 fibrosis. The 52-week study met its primary endpoint: steatohepatitis resolution without fibrosis worsening was achieved by 39.1% on 4 mg (P=0.002) and 32.4% on 2 mg (P=0.033), versus 13.7% for placebo. Fibrosis improvement without NAS worsening was 34.8% (4 mg) versus 24.6% (placebo). Saroglitazar was well tolerated without significant weight gain or drug-induced liver injury, showing favorable non-invasive liver fibrosis biomarker improvements.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements